-
April 02,2026Highlightll Pharma Announces Completion of U.S. Phase I Study of HL-400, a Brain-Penetrant NLRP3 InhibitorRead More -
January 18,2026Highlightll Announces that Girocitinib (TLL-018) Met the Primary Endpoints in the Interim Analysis of Its Phase Ⅲ Trial in Chronic Spontaneous Urticaria (CSU)Read More -
January 11,2026Highlightll Announces Completion of the SAD Portion in the PhaseⅠ Study of Its Brain-Penetrant NLRP3 Inhibitor HL-400Read More -
June 12,2023Selective JAK1/TYK2 Inhibition: A Novel Way to Overcome Tofacitinib Resistance in RA?Therapy with an investigative JAK1/TYK2 inhibitor led to remission in one-third of participants with difficult-to-treat rheumatoid arthritis (RA).Read More -
January 29,2023Highlightll Pharmaceutical TLL-018 Achieved Breakthrough Results in a Phase II Trial for Rheumatoid ArthritisRead More
